93 related articles for article (PubMed ID: 10769058)
1. Cytokine profile of draining lymph node lymphocytes in mice grafted with syngeneic keratinocytes expressing human papillomavirus type 16 E7 protein.
López MC; Stanley MA
J Gen Virol; 2000 May; 81(Pt 5):1175-82. PubMed ID: 10769058
[TBL] [Abstract][Full Text] [Related]
2. "Natural" presentation of human papillomavirus type-16 E7 protein to immunocompetent mice results in antigen-specific sensitization or sustained unresponsiveness.
Chambers MA; Wei Z; Coleman N; Nash AA; Stanley MA
Eur J Immunol; 1994 Mar; 24(3):738-45. PubMed ID: 8125141
[TBL] [Abstract][Full Text] [Related]
3. Delayed-type hypersensitivity response to the human papillomavirus type 16 E7 protein in a mouse model.
McLean CS; Sterling JS; Mowat J; Nash AA; Stanley MA
J Gen Virol; 1993 Feb; 74 ( Pt 2)():239-45. PubMed ID: 8381463
[TBL] [Abstract][Full Text] [Related]
4. Delayed-type hypersensitivity response to human papillomavirus type 16 E6 protein in a mouse model.
Chambers MA; Stacey SN; Arrand JR; Stanley MA
J Gen Virol; 1994 Jan; 75 ( Pt 1)():165-9. PubMed ID: 7906707
[TBL] [Abstract][Full Text] [Related]
5. Single-cell cytokine analysis allows detection of cervical T-cell responses against human papillomavirus type 16 L1 in women infected with genital HPV.
Passmore JA; Burch VC; Shephard EG; Marais DJ; Allan B; Kay P; Rose RC; Williamson AL
J Med Virol; 2002 Jun; 67(2):234-40. PubMed ID: 11992584
[TBL] [Abstract][Full Text] [Related]
6. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors.
Matsumoto K; Leggatt GR; Zhong J; Liu X; de Kluyver RL; Peters T; Fernando GJ; Liem A; Lambert PF; Frazer IH
J Natl Cancer Inst; 2004 Nov; 96(21):1611-9. PubMed ID: 15523090
[TBL] [Abstract][Full Text] [Related]
7. An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer.
de Vos van Steenwijk PJ; Heusinkveld M; Ramwadhdoebe TH; Löwik MJ; van der Hulst JM; Goedemans R; Piersma SJ; Kenter GG; van der Burg SH
Cancer Res; 2010 Apr; 70(7):2707-17. PubMed ID: 20233872
[TBL] [Abstract][Full Text] [Related]
8. Recruitment of Antigen Presenting Cells to Skin Draining Lymph Node From HPV16E7-Expressing Skin Requires E7-Rb Interaction.
Kuo P; Teoh SM; Tuong ZK; Leggatt GR; Mattarollo SR; Frazer IH
Front Immunol; 2018; 9():2896. PubMed ID: 30619266
[TBL] [Abstract][Full Text] [Related]
9. CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model.
Kim TG; Kim CH; Won EH; Bae SM; Ahn WS; Park JB; Sin JI
Immunology; 2004 May; 112(1):117-25. PubMed ID: 15096191
[TBL] [Abstract][Full Text] [Related]
10. The host response to lesions induced by human papillomavirus.
Stanley M; Coleman N; Chambers M
Ciba Found Symp; 1994; 187():21-32; discussion 32-44. PubMed ID: 7796671
[TBL] [Abstract][Full Text] [Related]
11. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
[TBL] [Abstract][Full Text] [Related]
12. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
[TBL] [Abstract][Full Text] [Related]
13. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
14. Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide.
Jochmus I; Osen W; Altmann A; Buck G; Hofmann B; Schneider A; Gissmann L; Rammensee HG
J Gen Virol; 1997 Jul; 78 ( Pt 7)():1689-95. PubMed ID: 9225046
[TBL] [Abstract][Full Text] [Related]
15. [Dendritic cells present particulate E7 protein of human papillomavirus and induce strong immunity].
Li J; Gao HQ; Zhao CL; Li LZ; Ji CY; Hou M; Plebaski M
Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):932-6. PubMed ID: 15329282
[TBL] [Abstract][Full Text] [Related]
16. Suppression of Antitumor Immune Responses by Human Papillomavirus through Epigenetic Downregulation of CXCL14.
Cicchini L; Westrich JA; Xu T; Vermeer DW; Berger JN; Clambey ET; Lee D; Song JI; Lambert PF; Greer RO; Lee JH; Pyeon D
mBio; 2016 May; 7(3):. PubMed ID: 27143385
[TBL] [Abstract][Full Text] [Related]
17. Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model.
Kim MS; Sin JI
Immunology; 2005 Oct; 116(2):255-66. PubMed ID: 16162274
[TBL] [Abstract][Full Text] [Related]
18. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus 16-specific T-cell responses and spontaneous regression of anal high-grade squamous intraepithelial lesions.
Tong WW; Shepherd K; Garland S; Meagher A; Templeton DJ; Fairley CK; Jin F; Poynten IM; Zaunders J; Hillman RJ; Grulich AE; Kelleher AD; Carr A;
J Infect Dis; 2015 Feb; 211(3):405-15. PubMed ID: 25139018
[TBL] [Abstract][Full Text] [Related]
20. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells.
De Bruijn ML; Schuurhuis DH; Vierboom MP; Vermeulen H; de Cock KA; Ooms ME; Ressing ME; Toebes M; Franken KL; Drijfhout JW; Ottenhoff TH; Offringa R; Melief CJ
Cancer Res; 1998 Feb; 58(4):724-31. PubMed ID: 9485027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
